Welcome to our dedicated page for Tenon Medical news (Ticker: TNON), a resource for investors and traders seeking the latest updates and insights on Tenon Medical stock.
Tenon Medical, Inc. reports developments as a medical device company focused on minimally invasive solutions for sacro-pelvic and sacroiliac joint disorders. Company news centers on the Catamaran System and the SImmetry® and SImmetry®+ SI Joint Fusion Systems, including product clearances, initial clinical use, commercial rollout activity, and intellectual property covering SI joint implant technologies.
Recurring updates also include quarterly and annual financial results, revenue trends from SI joint product sales, capital raises through private placements and convertible notes, and funding uses tied to commercial expansion, product development, clinical studies, working capital, and general corporate purposes.
Tenon Medical (NASDAQ:TNON) reported first quarter 2026 revenue of $1.4 million, up about 90% year-over-year, with gross profit of $0.9 million and gross margin expanding to 68.5%.
The company posted a net loss of $3.5 million, closed a $4.3 million senior convertible note financing, and expanded its IP, training, and commercial footprint.
Tenon Medical (NASDAQ:TNON) will release first quarter 2026 financial results for the period ended March 31, 2026 after market close on Tuesday, May 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time the same day with a Q&A session.
Dial-in numbers, international access, a webcast, and an audio replay available through May 26, 2026 are provided; the telephone replay access code is 13759830.
Tenon Medical (NASDAQ:TNON) reported record Q4 2025 revenue of $1.5M (up 92% YoY) and record full-year 2025 revenue of $3.9M (up 20% YoY). Gross profit was $1.0M in Q4 and $2.4M for 2025, with margins improving to 69% and 60% respectively.
The company secured FDA 510(k) clearance for SImmetry+ and completed initial procedures, closed a $2.85M ATM PIPE in Q4, and announced a subsequent $4.3M senior convertible note placement in March 2026.
Tenon Medical (NASDAQ:TNON) closed a private placement of senior original-issue-discount convertible notes, raising $4.3 million aggregate gross proceeds.
The 20% OID notes mature on September 11, 2026 and are convertible after six months into common stock at a conversion price equal to 80% of the 3-day VWAP prior to conversion. Net proceeds will fund commercial expansion, product development, clinical studies, working capital and general corporate purposes.
Tenon Medical (NASDAQ:TNON) closed a private placement of senior convertible notes for $4.3 million gross on March 12, 2026. The notes carry a 20% original issue discount, mature on September 11, 2026, and convert after six months at 80% of the 3‑day VWAP.
The company said net proceeds will fund commercial expansion, product development, clinical studies, working capital and general corporate purposes. Placement agent fees apply; notes and conversion shares are unregistered.
Tenon Medical (NASDAQ:TNON) announced a strategic expansion of its intellectual property portfolio on February 18, 2026, following USPTO Notices of Allowance for multiple patent applications expected to issue in 2026. The company reported a portfolio of 29 issued U.S. patents, 9 international patents, and 31 pending applications.
Tenon also cited its recent asset acquisition of SIVantage's SImmetry and SImmetry+ systems, supported by 16 issued U.S. patents, which the company says complements the Catamaran platform and strengthens protection for its sacro-pelvic fusion technologies.
Tenon Medical (NASDAQ:TNON) said it will report fourth quarter and full year 2025 results after market close on March 19, 2026 and host a conference call the same day at 4:30 p.m. ET. The company provided revenue ranges: Q4 2025 $1.45–$1.48M (~90% YoY) and FY2025 $3.91–$3.94M (~20% YoY). Dial‑in, international numbers, webcast details, and replay access through April 2, 2026 were provided, with telephone replay access code 13758268.
Tenon (NASDAQ:TNON) reported preliminary, unaudited Q4 2025 revenue of $1.45–$1.48 million (~90% YoY) and full year 2025 revenue of $3.91–$3.94 million (~20% YoY). The company highlighted the SiVantage acquisition, FDA clearance for an expanded Catamaran indication, strong MAINSAIL 12-month fusion results (83% fusion), and plans to report audited results in March 2026.
Tenon Medical (NASDAQ:TNON) announced completion of initial clinical procedures using its new SImmetry+ SI Joint Fusion System on December 4, 2025, with cases at Centers of Excellence in Florida, Arizona, Ohio, and Texas.
The minimally invasive lateral system uses 3D-printed titanium implants, joint decortication, and a bone graft delivery system, cleared for use with one to three implants. Tenon cites published 12-month EvoluSIon data (250 patients): 68.7% radiographic fusion at 12 months and a 57.1% decrease in pre-operative opioid use.
Tenon is conducting a controlled early-access rollout with select SI fusion physicians to gather procedural feedback ahead of broader commercial launch.
Tenon Medical (NASDAQ:TNON) announced the closing of an at-the-market PIPE financing on November 14, 2025 that generated approximately $2.85 million in gross proceeds.
The company issued 2,217,904 shares of common stock and issued warrants to purchase an equal number of shares; each share-plus-warrant was sold at a combined price of $1.285. The PIPE Warrants carry a $1.16 exercise price and expire three years from issuance. Proceeds are intended for working capital, upcoming product launches, commercial expansion, clinical studies, and general corporate purposes.